OB
Ollin BiosciencesClinical-stage biopharmaceutical company developing best-in-disease therapies for vision-threatening eye diseases, including a VEGF/Ang2 bispecific antibody in Phase 3 for DME and wet AMD.
2 Pulse stories
S
ShionogiJapanese pharmaceutical company developing prescription drugs, infectious disease therapies, and specialty medicines, including a former sleep apnea drug joint venture with Apnimed.
2 Pulse stories
Total Raised
$430M
Ollin BiosciencesShionogi
Last ValuationNot disclosed
Biotech
Sector
Biotech
2023
Founded
1878
Chicago, Illinois
HQ
Osaka, Japan
Private
Status
Public (4507.T)
Ollin Biosciences investors
ARCH Venture PartnersTCGX (TCG Crossover)Andreessen HorowitzMubadala CapitalMonograph CapitalBlackstone Multi-Asset InvestingCommodore CapitalRA Capital Management
Shionogi investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Ollin Biosciences and Shionogi.